[1-Deaminopenicillamine,4-threonine]oxytocin was prepared in duplicate from S-benzyl-3-mercapto-3,3-dimethylpropanoyl-Tyr(Bzl)-Ile-Thr(Bzl)-Asn-Cys(Bzl)-Pro-Leu-Gly-NH2 (I) by removal of the Bzl-protecting groups with Na-NH3, followed by cyclization of the resulting disulfhydryl compound with K3Fo(CN)6. The analogue was purified by desalting on Sephadex G-15 in 50% acetic acid and gel filtration of Sephadex G-15. The protected peptide I was synthesized (a) by the solid-phase method and (b) by a combination of solid-phase synthesis and an [8 + 1] coupling in solution. The analogue has no detectable agonist activity in rat vasopressor or isolated rat uterus assays. It has an antivasopressor pA2 of 6.67 +/- 0.09. It is a potent inhibitor of the in vitro oxytocic response to oxytocin and has a pA2 value of 7.46 +/- 0.04. (Material from the repeat synthesis has a pA2 value of 7.59 +/- 0.08.) Thus the substitution of threonine for glutamine in the antagonist [1-deaminopenicilliamine]oxytocin (pA2, 7.14 +/- 0.05) has effected a twofold increase in inhibitory potency. [1-deaminopenicillamine,4-threonine]oxytocin is one of the most potent inhibitors of oxytocin known to date.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm00200a007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Male-female comparison of vasomotor effects of circulating hormones in human intracranial arteries.
J Headache Pain
December 2024
Department of Clinical Sciences, Faculty of Medicine, Lund University, Getingevagen 4, Lund, 22185, Sweden.
Background: The purpose of this study was to examine whether there are sex differences in vasomotor responses and receptor localization of hormones and neuropeptides with relevance to migraine (vasopressin, oxytocin, estrogen, progesterone, testosterone, amylin, adrenomedullin and calcitonin gene-related peptide (CGRP)) in human intracranial arteries.
Methods: Human cortical cerebral and middle meningeal arteries were used in this study. The tissues were removed in conjunction with neurosurgery and donated with consent.
Oxytocin Protects Against Corticosterone-Induced DA Dysfunction: An Involvement of the PKA/CREB Pathway.
Neurochem Res
November 2024
Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, 73170, Thailand.
Article Synopsis
- - Chronic stress negatively affects dopamine transmission, leading to mood disorders and conditions like ADHD, autism, schizophrenia, anxiety, depression, and drug addiction, while oxytocin plays a role in social behaviors and can counteract stress effects.
- - This study examined how oxytocin can protect against dopamine dysfunction caused by corticosterone in neuroblastoma cells, revealing that corticosterone reduces key signaling molecules related to dopamine function, but oxytocin can mitigate this dysfunction.
- - The protective effect of oxytocin operates through activation of protein kinase A (PKA) and involves oxytocin receptors, providing insights into stress resilience and possible treatments for disorders linked to dopamine issues.
Splenectomy prevents brain orexin, ghrelin, or oxytocin but not GLP-1-induced improvement of intestinal barrier function in rats.
Neurogastroenterol Motil
October 2024
Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Background: Accumulating evidence has suggested that neuropeptides such as orexin, ghrelin, or oxytocin act centrally in the brain to regulate intestinal barrier function through the vagus nerve. It has been reported that the vagal cholinergic anti-inflammatory pathway was blocked by splenectomy. In the present study, we therefore examined the effect of splenectomy on neuropeptides-induced improvement of increased intestinal permeability.
View Article and Find Full Text PDFOxytocin Analogues for the Oral Treatment of Abdominal Pain.
Angew Chem Int Ed Engl
December 2024
University of Vienna, Faculty of Chemistry, Institute of Biological Chemistry, Währinger Straße 38, 1090, Vienna, Austria.
Abdominal pain presents an onerous reality for millions of people affected by gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). The oxytocin receptor (OTR) has emerged as a new analgesic drug target with OTR expression upregulated on colon-innervating nociceptors in chronic visceral hypersensitivity states, accessible via luminal delivery. However, the low gastrointestinal stability of OTR's endogenous peptide ligand oxytocin (OT) is a bottleneck for therapeutic development.
View Article and Find Full Text PDFInvestigation of effect peripheral kisspeptin treatment on hypothalamo-pituitary-gonadal axis and hypothalamo-pituitary-adrenal axis in male rats.
Biol Futur
December 2024
Department of Physiology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
Article Synopsis
- Kisspeptin is a powerful hormone that stimulates the hypothalamo-pituitary-gonadal (HPG) axis, but its interaction with the stress-related hypothalamo-pituitary-adrenal (HPA) axis is still unclear.
- In a study involving male Wistar rats, various treatment groups were administered kisspeptin along with different substances to evaluate its effects on hormone levels.
- The results showed that kisspeptin injections significantly increased levels of follicle-stimulating hormone, luteinizing hormone, and testosterone, indicating activation of the HPG axis, but did not affect the HPA axis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!